Pfizer’s inner weight problems drug R&D stumbled, however the pharmaceutical big is leaping forward on this area by way of the multi-billion greenback acquisition of Metsera, a clinical-stage firm whose pipeline of next-generation metabolic medicines may supply a number of factors of differentiation in a crowded market of weight reduction therapies.
Phrases of the acquisition settlement introduced Monday name for Pfizer to pay $47.50 in money for every share of Metsera, valuing the biotech at about $4.9 billion. Pfizer may pay out as much as $22.50 extra per share if the medication of New York-based Metsera obtain medical and regulatory milestones.
Talking throughout a convention name Monday, Pfizer Chief Technique and Innovation Officer Andrew Baum acknowledged that many profitable weight problems merchandise are available on the market, however he mentioned important unmet medical want stays. He added that weight problems’s affiliation with different ailments means Metsera’s pipeline gives the potential for growth to different indications.
“We evaluated a number of exterior alternatives within the weight problems house and have been exhaustive in our evaluation and diligence to verify we recognized the optimum alternative that delivers compelling potential differentiation throughout key asset attributes,” Baum mentioned.
Probably the most superior Metsera drug candidate, MET-097i, is a peptide engineered to activate the GLP-1 receptor, placing it in the identical class of medicines because the weekly injectables Wegovy, from Novo Nordisk, and Zepbound, from Eli Lilly. Whereas a Section 2 examine is underway evaluating MET-097i as a weekly injection, this drug was designed with proprietary know-how giving the molecule an extended half-life to assist an extended dosing interval. A separate mid-stage examine is underway testing month-to-month dosing.
Along with decreasing the dosing burden for sufferers, month-to-month dosing gives manufacturing benefits by decreasing the variety of required injector units, resulting in price and provide chain benefits over weekly injectable merchandise. Preliminary outcomes for weekly and month-to-month dosing are anticipated in 2026, in keeping with a Pfizer investor presentation. Metsera is aiming for even much less frequent dosing. An injectable GLP-1 candidate with the potential for every-three-months dosing is presently in preclinical growth.
Drug firms are additionally making an attempt to develop metabolic medicines to new targets, such because the amylin receptor. Novo Nordisk has two packages within the clinic addressing amylin. This goal has additionally drawn the curiosity of AbbVie and Roche, every of which has struck offers this 12 months so as to add amylin-targeting packages to their pipelines. Metsera’s amylin contender, MET-233i, presently in Section 1 medical growth. Metsera executives have mentioned this drug has best-in-class potential, a sentiment echoed Monday by Pfizer executives. Preliminary Section 1 knowledge have been offered final week in the course of the annual assembly of the European Affiliation for the Examine of Diabetes. A separate Section 1 check is underway evaluating the mix of MET-233i and MET097i.
The Metsera pipeline additionally consists of drugs, which is necessary as weight problems drug analysis pursues extra handy dosing choices that might function alternate options to injections for preliminary therapy or as upkeep therapies after sufferers obtain goal weight reduction with an injectable treatment. Metsera has oral GLP-1 and amylin drug candidates in preclinical growth.
Pfizer had beforehand recognized oral medication as a option to differentiate and compete towards injectable weight problems drugs. However in 2023, the corporate discontinued growth of the oral GLP-1 drug lotiglipron after a security sign emerged in Section 1 testing. The corporate then turned its focus to a unique oral GLP-1 drug, danuglipron. This drug achieved statistically important weight reduction in mid-stage testing, however these outcomes additionally confirmed many sufferers struggled to stay with its twice-daily dosing. Pfizer’s growth of once-daily oral danuglipron resulted in Might after an indication of potential drug-induced liver damage emerged in Section 1 testing.
Leerink Companions initiatives that Metsera’s medication may attain $5 billion in mixed peak gross sales. In a Sept. 9 analysis word, analyst David Risinger wrote that knowledge thus far for month-to-month injections of lead Metsera program MET-097i counsel efficacy equal to weekly injections of Lilly’s Zepbound and doubtlessly higher tolerability. Moreover, growth of this weekly injection for preliminary titration ought to yield tolerability benefits over opponents and likewise supply most flexibility for sufferers who wish to dose weekly or re-start remedy Risinger mentioned.
Metsera’s amylin candidate additionally gives the potential for month-to-month dosing, Risinger mentioned. He added that the corporate’s oral GLP-1 drug may supply higher efficacy and tolerability than Lilly’s oral GLP-1 agonist, orforglipron, which is on monitor for an FDA submission.
There’s one other potential aggressive benefit for Metsera’s mixture of MET-233i and MET097i, which the corporate believes will likely be evaluated as a biologic drug. Risinger mentioned Metsera administration famous {that a} peptide sequence of better than 40 amino acids can be eligible to be reviewed below a biologics license utility (BLA), versus the brand new drug utility (NDA) pathway used for Novo’s semaglutide (Wegovy) and Lilly’s tirzepatide (Zepbound). Classification as a biologic would additionally give the Metsera drug combo safety towards compounders. The Meals Drug & Cosmetics Act makes biologics ineligible for compounding.
“We view this as a beautiful differentiation from tirzepatide and semaglutide, which underwent an NDA evaluation course of, significantly given the favorable positioning for [Inflation Reduction Act] negotiations for BLA over NDA (13 years vs. 9 years, respectively),” Risinger wrote. “MET-097i may additionally be protected towards compounding because the FDA states that ‘Organic merchandise usually are not eligible for the exemptions for compounded medication below sections 503A and 503B of the FD&C Act.’”
The $47.40 per share that Pfizer agreed to pay represents a 42.5% premium to Metsera’s closing value on Friday. Metsera’s IPO early this 12 months was priced at $18 every per share. Metsera shareholders may obtain extra tied to the achievement of medical and regulatory milestones. A contingent worth proper within the deal pays an extra $5 per share after the mix of MET-097i and MET-233i begins a Section 3 medical trial. One other $7 per share will likely be paid upon FDA approval of month-to-month MET-097i as a monotherapy; $10.50 per share is tied to FDA approval of the MET-097i and MET-233i mixture.
The boards of administrators of each firms have authorised the acquisition, which nonetheless wants the approval of Metsera shareholders in addition to regulatory approvals. The deal is predicted to shut within the fourth quarter of this 12 months.
Picture: Dominick Reuter/AFP, by way of Getty Photographs
